$5.10
-0.03 (-0.58%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where EMBC is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 11 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, MILLENNIUM MANAGEMENT LLC, D. E. Shaw & Co., Inc., CITADEL ADVISORS LLC, MARSHALL WACE, LLP, +6 more) · FINRA short interest 5.9 days to cover (settled 2026-07-31) · government filings 180d: 0 congress / 2 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Embecta AID System in Adults With Type 2 DiabetesNCT06692153HbA1c changeRandomized · Open-label · Treatment | Not applicable | Withdrawnsponsor's stated reason: Program was discontinued. | Device: An AID System. · Other: Standard of Care (SC) | Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM), Type 2 DM, T2DM With Inadequate Glycemic Control, T2DM (Type 2 Diabetes Mellitus), T2D, T2DM | 0 | Mar 2026 | 2024-12-16 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19